Uncommon Write-Up Unearths The Deceiving Methods Concerning CAL-101

One hundred ninety-three patients were included in the study; 48 of them received dexrazoxane with first-line chemotherapy. The mean dose of dexrazoxane per cycle was 1,050 mg, and 61.7% of the patients started dexrazoxane in http://www.selleck.cn/products/CAL-101.html the first or second chemotherapy cycle. Baseline patient characteristics are described in Supporting Information Table 1. Patients who received dexrazoxane were older (mean age 70.35 versus 54.1 years, P http://www.selleckchem.com/products/gsk269962.html anthracycline dose was 265.36 (��68.96) mg per body surface area (BSA) in patients that did not receive dexrazoxane and 256.92 (��79.38) mg per BSA in patients that did (P = 0.482). Comparison of treatment complications between patients treated with and without dexrazoxane showed that only diarrhea was significantly more frequent http://www.selleckchem.com/products/gsk2126458.html in the group that received dexrazoxane (27.1 versus 8.3%, P = 0.001). All other complications were similar in incidence between the groups (Supporting Information Table 3). Comparison of treatment outcome between the groups showed that there was no statistically significant difference in rates of CR, PR, relapse, death, and the composite endpoint of death and relapse between patients treated with or without dexrazoxane. Among patients who did not relapse, the death rate was also similar (Table I). Cox regression models were used to investigate the association between dexrazoxane treatment and relapse risk, and between dexrazoxane treatment and a composite endpoint of relapse or all-cause mortality. The following variables were included in the model: gender, age, IPI score, histology, staging, extranodal involvement at diagnosis, and bone marrow involvement at diagnosis. Dexrazoxane treatment was forced into the model. Survival models revealed that treatment with dexrazoxane, adjusted for the aforementioned baseline characteristics, was not significantly associated with either relapse risk [hazard ratio 1.31 with 95% confidence interval (CI) of 0.64�C2.70, P = 0.46] or a composite endpoint of relapse or all-cause mortality (hazard ratio 1.25 with 95% CI of 0.65�C2.41, P = 0.50).